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ABSTRACT 
Objective: The prime objective of the paper was to design and synthesize new derivatives of (E)-3-(5-(substitutedaminomethyl)-1,3,4-
thiadiazol-2-yl)-2-styrylquinazolin-4(3H)-one and evaluated for their anticonvulsant potential. 
Material and methods: Various derivatives  of (E)-3-(5-(substitutedaminomethyl)-1,3,4-thiadiazol-2-yl)-2-styrylquinazolin-4(3H)-one 
derivatives has been synthesized by reacting 2-substituted benzoxazin-4-one with (E)-2-(4-Substituedstyryl)-4H-benzo[d][1,3]oxazin-4-one. 
All synthesized compounds have been characterized by the IR, NMR and mass spectral analysis. Proposed compounds have been evaluated for 
anticonvulsant potential by subcutaneous pentylenetetrazole (scPTZ) and maximal electroshock seizure (MES) model and compared with the 
reference drug phenytoin &carbamazepine. 
Result and discussion: The subcutaneous pentylenetetrazoles (scPTZ) model denotes that compounds SB-6, SB-12, SB-14 and SB-18 were 
found most active at anticonvulsant screening when compared with phenytoin and carbamazepine (standard drug).The most active compound 
of the series was SB-1, SB-4, SB-6, SB-9, SB-12, SB-14, SB-14 and SB-18. In most of the Cl and nitro group phenyl ring in position of the 1,3,4-
thiadiazoles nucleus and Cl on phenyl ring of 4(3H)-quinazolinone has shown the potent activity. 
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INTRODUCTION 
Quinazoline is an organic compound with the formula 
C8H6N2. It is an aromatic heterocycles with a bi-cyclic 
structure consisting of two fused six-member aromatic rings, 
a benzene ring and pyrimidine ring. Quinazoline is a 
compound made up of two fused six-member aromatic rings, 
a benzene ring and a pyrimidine ring. Quinazoline is a fused 
bi-cyclic compound earlier known as benzo-1,3-diazine was 
first prepared in the laboratory by Gabriell. Depending upon 
the position of the keto or oxo group, these compounds may 
be classified into three types including 4(3H)-quinazolinone, 
2(1H)quinazolinone and 2,4 (1H,3H)-quinazolinedione, of 
the three quinazolinone structures 4(3H)-quinazolinone are 
most prevalent, either as intermediates or as natural 
products in many proposed bio synthetic pathways.  
Epilepsy is a central nervous system (CNS) malfunction that 
leads either to generalized hyperactivity involving 
essentially all parts of the brain or hyperactivity of only a 
portion of the brain. It has been estimated that adequate 
control of seizures could not be obtained in up to 20% of the 
patients with epilepsy using first generation of antiepileptic 
drugs (phenobarbital, phenytoin, carbamazepine, sodium 
valproate and diazepam. The convulsions of approximately 
25% of epileptics are adequately controlled by current 
clinically available drugs. Current drug therapy is 
accompanied by numerous side effects including drowsiness, 
ataxia, gastrointestinal disturbances, gingival hyperplasia, 
hirsutism and megaloblastic anemia1. The past decade has 
witnessed a continuous interest in the development of 
anticonvulsant drugs. 
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Quinazolinone is a potent hypnotic agent and other 4(3H)-
Quinazolinone and its derivatives have been reported to 
exhibits analgesic, anesthetic, antibacterial2, anticancer, 
anticonvulsant, antihypertensive, anti-inflammatory & 
antioxidant3, diuretic, muscle relaxant, sedative, anti-
hepatitis-A virus4 and tranquilizer properties. The 4(3H)-
quinazoline and its derivatives have been reported to exhibit 
anticonvulsant, antimicrobial, sedative, tranquilizer, 
analgesic, anesthetic, anticancer, antihypertensive, anti-
inflammatory, diuretic and muscle relaxant properties5-15. 2-
Methyl-3-o-tolyl-4(3H)-quinazolinone (Methaqualone) is the 
most frequently prescribed quinazolinone derivative as a 
safe sedative-hypnotic and anticonvulsant drug. 
Literature survey revealed that the presence of substituted 
aromatic ring at 3rd position and methyl/phenyl group at 2nd 
position of 4(3H)-quinazolinone are necessary requirement 
for the central nervous system (CNS) depression and 
anticonvulsant activity. This hypothesis encourages us to 
build the modification of quinazolinone at 2nd and 
3rdposition. The objective of the papers was to design, 
synthesize and evaluation of synthesized compounds for 
anticonvulsant potential. 
EXPERIMENTAL 
Material and method 
2-chloroacetyl chloride, thiosemicarbazide, formaldehyde 
was purchased from Sigma Aldrich, New Delhi. Substituted 
anilines (4-chloro, 4-fluro aniline, 4-nitro aniline, 4-methyl 
aniline, 4-methoxy aniline, 4-ethyl aniline, 4-ethoxy aniline) 
were purchased from Hi-Media. Acetic anhydride, di-methyl 
formamide, glacial acetic acid substituted and benzaldehyde 
(4-Chloro, 4-nitro, 4-CH3 and 4-OCH3) was purchased from 
CDH (Chemical Drug House), New Delhi, India. The chemical 
used for experimental work were synthetic grade. The 
melting points of the synthesized compounds were 
determined in open glass capillaries. IR spectra were 
recorded on ALPHA (Bruker) FTIR Spectrometer. Elemental 
analysis was performed and found values were within 0.4% 
of theoretical values. 13C NMR spectra were recorded on 
Bruker Avance 400 spectrophotometer at 400 MHz, 5mm 
multi-nuclear inverse probe head, low and high-temperature 
facility and HRMAS accessory. Mass Spectra were recorded 
using Mass Spectrometers Jeol SX-102 (FAB) by ESI. 
Chemistry 
The synthesis of (E)-3-(5-(substitutedaminomethyl)-1,3,4-
thiadiazol-2-yl)-2-styryl quina zolin-4(3H)-one is 
accompanied in Figure 1 and present synthesis comprises of 
three steps. These are - 
1. Scheme 1 
Synthesis of 1,3,4-thiadiazole 
Step 1: Synthesis of 5-(chloromethyl)-1,3,4-thiadiazol-2-
amine 
Step 2: Synthesis of 5-(substituted-amino methyl)-1,3,4-
thiadiazol-2-amine 
2. Scheme 2 
Synthesis of titled compounds 
Step 1: Synthesis of 2-substituted-benzoxazin-4-one 
Step 2: Synthesis of (E)-2-(4-Substituedstyryl)-4H-
benzo[d][1,3]oxazin-4-one 
Step 3: Synthesis of (E)-3-(5-(substitutedaminomethyl)-
1,3,4-thiadiazol-2-yl)-2-styrylquinazolin-4(3H)-one 
A. General method for the synthesis of 1,3,4-thiadiazole:
 
Step 1: Synthesis of 5-(chloromethyl)-1,3,4-thiadiazol-2-amine16 
 
Substituted amino thiadiazole [3] was prepared by the 
conventional method by following procedure: In this 
reaction 2-chloroacetyl chloride [2] (0.1 mol) and 
thiosemicarbazide [1] (0.1 mol) was mixed thoroughly. The 
reaction mixture was heated under reflux in the presence of 
conc. H2SO4.  The reaction was cooled to room temperature 
and neutralized with ammonia solution. The solid was 
filtered and washed with water followed by few drops of 
ether. The product was recrystallized from ethanol and 
characterized by 1H NMR, mass and UV-spectral analysis.
 
Step 2: Synthesis of 5-(substituted-amino methyl)-1,3,4-thiadiazol-2-amine17 
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5-(chloromethyl)-1,3,4-thiadiazol-2-amine [3] (0.1 mol) was 
taken in round bottom flask and formaldehyde was 
dissolved in methanol (3.0 ml) was added drop wise with 
continuous stirring. The resulting mixture was stirred 
during half an hour to complete the mixing. To this reaction 
mixture methanolic solution of p-chloro aniline/ p-fluoro 
aniline/p-nitro aniline/p-methyl aniline/p-methoxy 
aniline/p-ethyl aniline/p-ethoxy aniline (0.1 mol) [4] was 
added drop wise with stirring in about half an hour for 
temperature at 30°C and refluxed for 2h at 65-75°C . It was 
allowed to cool and poured in cold water. The solid was 
obtained, filtered off and washed thoroughly with hot water 
and air dried. Obtained compound [5], was characterized by 
IR, NMR and were found consistent with an expected 
structure. TLC has been performed each and every steps to 
confirm the completion of the reaction. 
 
 
Synthesis of Titled Compounds 
Step 1: Synthesis of 2-methyl-4H-benzo[d][1,3]oxazin-4-one18 
 
 
Anthranilic acid [6] (0.01 M) was dissolved in acetic 
anhydride and refluxed under anhydrous condition for 4h. 
Excess of acetic anhydride was then distilled off under 
reduced pressure to get solid mass of N-acetyl anthranilic 
acid. Then N-acetyl anthranilic acid was further reflux with 
acetic anhydride, under anhydrous condition for 4 hr. Excess 
of acetic anhydride was then distilled off under reduced 
pressure to get solid mass of 2-methyl benzoxazin-4-one [7]. 
The products were dried and recrystallized from petroleum 
ether. Reaction was monitored by the TLC for the 
completion of the reaction. 
Note: Purification of anthranilic acid: The anthranilic acid, 
used for the synthesis was purified by following procedure. 
The crude anthranilic acid (100 g) was dissolved in hot 
distilled water (500 ml) and activated charcoal (2g) was 
added to it with constant stirring.  It was refluxed for 20-30 
min and filtered hot. On cooling the crystals of anthranilic 
acid separated out which was filtered and dried. (Percent 
yield:  60%, melting point: 144-1450C). 
 
Step 2: Synthesis of (E)-2-(4-Substituedstyryl)-4H-benzo[d][1,3]oxazin-4-one19 
 
 
A 2-methyl-4H-benzo[d][1,3]oxazin-4-one [7] (0.1 M), 
respective substituted  aldehyde (0.2 M) and anhydrous zinc 
chloride (0.1 g) was refluxed at 130-1400C for 2h. After 
cooling, the reaction mixture was treated with cold water to 
dissolve zinc chloride. The residue left after filtration was 
washed with cold ethanol. Purification of the synthesized 
compounds [8] was done by dissolving the compounds in 
minimum quantity of dimethyl formamide (DMF) and then 
adding the solution to distilled water.   
The above method gave very low yield therefore some 
modification has carried to get high yield and purity of the 
product. Equimolar amount of 2-methyl-3-(substituted 
1,3,4-thiodiazole-2-yl)-4(3H)-quinazolinone [7] (0.2M) and 
respective substituted aldehyde (0.2 M)were taken in glacial 
acetic acid (10 ml) and refluxed for 12 hr (Raffa et al., 2004). 
After cooling, product [8] was separated out, which was 
filtered off.  The purification of the product was done by 
using DMF and the melting points determined. This 
synthesis was monitored by the TLC to confirm the 
completion of the reaction. 
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Step 3: Synthesis of (E)-3-(5-(substitutedaminomethyl)-1,3,4-thiadiazol-2-yl)-2-styrylquinazolin-4(3H)-one 
 
 
Equimolar quantity of compound [8] (0.01 M) was taken in 
round bottom flask and obtained compound [5], and 
dissolved in glacial acetic acid and refluxed for 4h. After 
cooling, it was poured into crushed ice and kept overnight in 
the refrigerator. The solid product [9] which was separated 
out, filtered, washed thoroughly with cold distilled water, 
dried and recrystallized from hot ethanol. Synthesis was 
monitored by the TLC for the completion of the reaction. 
Characterization 
The synthesized compounds were subjected to qualitative 
tests for nitrogen, sulphur and halogen wherever desired. 
Quantitative analysis for nitrogen and sulphur was done by 
Elemental Vario EL III Carlo Erba 1108. IR spectra were 
recorded on Perkin Elmer Spectrum RXI IR 
spectrophotometer in KBr pellets. NMR spectra were 
recorded on C13 Advance Bruker DRX 300 MHz 
spectrometer. Mass spectra were recorded on JeolSx 
102/DA-6000 mass spectrometer using fast moving 
bombardment (FAB) technique. Solubility of the synthesized 
compound was checked in different solvent at room 
temperature (18-300°C).  The purity of the synthesized 
compound was confirmed by thin layer chromatography 
(TLC) using silica gel G in various solvent systems like 
Hexane/ethanol(95%)/Chloroform/ benzene, visualization 
was done using iodine vapors in a iodine chamber or in 30% 
sulphuric acid. List of all synthesized compounds was 
tabulated in Table. 1. Physical properties of the synthesized 
title compounds shown in Table 2. 
 
 
Figure 1: Synthesis scheme of compounds 
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SB-1: (E)-3-(5-(((4-chlorophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-styryl quinazolin-4(3H)-one 
Molecular formula: C25H18ClN5OS; Molecular weight: 471.96. 
IR (cm-1): 3020(C-H str.); 760 (C-H def.) 1700 (C=O str.); 
1174 (C6H5); 1516C=Cstr.; 2856 (C-H str.); 3120 (C-H str.); 
1461 (C-H str.); 1580 (C-C str.); 1614 (C=C str.); 1326 (C-N 
str.) 1555 (C=N str.); 760 (C-S str.); 620 (C-Cl str.). 13C 
NMR(DMSO-d6, δ ppm): 113.3 C11; 126.7 (C8, 4-
quinazolinone ring); 128.5 (C14 & C18, phenyl substituted 
styryl group attached to 4-quinazolinone ring); 145.5 (C9, 4-
quinazolinone ring & phenyl ring attached to 1,3,4 
thiadiazole ring); 127.9 (C16, phenyl substituted styryl 
group attached to 4-quinazolinone ring); 127.3 (C6, 4-
quinazolinone ring); 128.6 (C15 and C17, phenyl 
substituted styryl group attached to 4-quinazolinone ring & 
phenyl ring attached to 1,3,4-thiadiazole ring); 129.6 
(phenyl ring attached to 1,3,4 thiadiazole ring; 126.6 (C5, 4-
quinazolinone ring; 133.4 (C7, 4-quinazolinone ring); 135.2 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.1 (C12, styryl group attached to 4-
quinazolinone ring); 147.4 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.8 (C10, 4-quinazolinone ring; 158.9 
(C2, 4-quinazolinone ring); 160.6 (C4, 4-quinazolinone ring). 
FAB Mass (m/z): 472 (Quassi-molecular ion peak). 
SB-2: (E)-3-(5-(((4-bromophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-styryl quinazolin-4(3H)-one 
Molecular formula: C25H18BrN5OS; Molecular weight: 516.41; 
TLC (Rf value): 0.72 IR (cm-1): 3120 (C-H str.); 775 (C-H 
def); 1737 (C=O str.); 1598 (C=C str.); 2975 (C-H str.); 3020 
(C-H str.); 1378(C-H def.); 1458 (C-C str.); 1610(C=C str.); 
1269(C-N str.); 733 (C-S str.); 520 (C-Br str.); 13C NMR 
(ppm):  113.3(C11; styryl group attached to 4-quinazolinone 
ring;  126.7 (C8, 4-quinazolinone ring); 128.5 (C14 & C18, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring)  114.9 (C9, 4-quinazolinone ring & phenyl ring 
attached to 1,3,4 thiadiazole ring); 127.9 (C16, phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
127.3 (C6, 4-quinazolinone ring); 115.1 (C15 and C17, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring & phenyl ring attached to 1,3,4-thiadiazole ring) 132.4 
(phenyl ring attached to 1,3,4 thiadiazole ring); 126.6 (C5, 4-
quinazolinone ring); 133.4 (C7, 4-quinazolinone ring); 135.2 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.1 (C12, styryl group attached to 4-
quinazolinone ring); 148.3 (phenyl ring attached to 1,3,4 
thiadiazole ring);  120.8 (C10, 4-quinazolinone ring); 158.9 
(C2, 4-quinazolinone ring); 160.6 (C4, 4-quinazolinone ring). 
FAB Mass (m/z): 516 (Quassi-molecular ion peak). 
SB-3: (E)-3-(5-(((4-nitrophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-styrylquinazolin-4(3H)-one 
Molecular formula: C25H18N6O3S; Molecular weight: 482.51; 
TLC (Rf value): 0.67. IR (cm-1): 3261 (C-H str.); 812 (C-H 
def); 1700 (C=O str.); 1174 (-C6H5); 1540 (N=O str.); 1320 
(N-O str.); 1593 (C=C str.); 1076 (-C6H5); 2856 (C-H str.); 
3057 (C-H str.); 1382 (C-H def); 1442 (C-C str.); 1620 (C=C 
str.); 1274 (C-Nstr.); 740 (C-S str.) 13C NMR (ppm): 113.5 
(C11; styryl group attached to 4-quinazolinone ring); 126.9 
(C8, 4-quinazolinone ring); 128.1 (C14 & C18 phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
114.4 (C9,  4-quinazolinone ring & phenyl ring attached to 
1,3,4 thiadiazole ring); 127.9 (C16, phenyl substituted styryl 
group attached to 4-quinazolinone ring); 127.3 ( C6, 4-
quinazolinone ring); 136.3 (C15 and C17, phenyl substituted 
styryl group attached to 4-quinazolinone ring & phenyl ring 
attached to 1,3,4-thiadiazole ring) 127.5 (phenyl ring 
attached to 1,3,4 thiadiazole ring); 126.3 (C5,  4-
quinazolinone ring); 133.6 (C7, 4-quinazolinone ring) 135.1 
(C13 due to phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.6 (C12, styryl group attached to 4-
quinazolinone ring); 155.4 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.3 (C10, 4-quinazolinone ring); 158.7 
(C2, 4-quinazolinone ring); 160.9 (C4, 4-quinazolinone ring; 
FAB Mass (m/z):  482 (Quassi-molecular ion peak). 
SB-4: (E)-3-(5-(((4-chlorophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-chlorostyryl) quinazolin-4(3H)-
one 
Molecular formula: C25H17Cl2N5OS; Molecular weight: 
506.41; TLC (Rf value): 0.61; IR (cm-1): 3055 (C-H str.); 810 
(C-H def (oop)); 1739 (C)=O str.); 1596 (C=C str.); 2833 (C-H 
str.); 3001 (C-H str.); 1373 (C-H def.); 1438 (C-C str.); 1642 
(C=C str.); 1334 (C-N str.); 1542 (C=N str.); 759 (C-S str.); 
650 (C-Cl str.); 13C NMR (ppm): 113.2 (C11, styryl group 
attached to 4-quinazolinone ring); 126.4 (C8, 4-
quinazolinone ring); 129.3 (C14 & C18, phenyl substituted 
styryl group attached to 4-quinazolinone ring); 114.9 (C9,  4-
quinazolinone ring & phenyl ring attached to 1,3,4 
thiadiazole ring; 133.7 (C16, phenyl substituted styryl group 
attached to 4-quinazolinone ring); 127.7 (C6, 4-
quinazolinone ring); 126.1 (C15 and C17, phenyl substituted 
styryl group attached to 4-quinazolinone ring & phenyl ring 
attached to 1,3,4-thiadiazole ring); 129.6 (phenyl ring 
attached to 1,3,4 thiadiazole ring); 126.4 (C5, 4-
quinazolinone ring); 133.8 (C7, 4-quinazolinone ring); 135.3 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.5 (C12, styryl group attached to 4-
quinazolinone ring); 147.4 (phenyl ring attached to 1,3,4 
thiadiazole ring;  120.1 (C10, 4-quinazolinone ring); 158.4 
(C2, 4-quinazolinone ring) 160.6 (C4, 4-quinazolinone ring). 
FAB Mass (m/z): 506 (Quassi-molecular ion peak). 
SB-5: (E)-3-(5-(((4-bromophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-chlorostyryl) quinazolin-4(3H)-
one 
Molecular formula: C25H17BrClN5OS; Molecular weight: 
550.86; TLC (Rf value): 0.61; IR (cm-1): 3211 (C-H str.); 774 
(C-H def (oop); 1701 (C=O str.); 1596 (C=C str.); 2896 (C-H 
str.); 3060(C-H str.);  1447(C-H def.); 1470 (C-C str.); 1637 
(C=C str.); 1316 (C-N str.); 1530 (C=N str.); 719 (C-S str.); 
650 (C-Cl str.); 570 (C-Br str.); 13C NMR (ppm): 113.2 (C11, 
styryl group attached to 4-quinazolinone ring); 126.4 (C8, 4-
quinazolinone ring); 129.0 (C14 & C18, phenyl substituted 
styryl group attached to 4-quinazolinone ring); 114.5 (C9, 4-
quinazolinone ring & phenyl ring attached to 1,3,4 
thiadiazole ring); 133.5 (C16, phenyl substituted styryl 
group attached to 4-quinazolinone ring); 127.7 (C6, 4-
quinazolinone ring; 115.1 (C15 and C17, phenyl substituted 
styryl group attached to 4-quinazolinone ring & phenyl ring 
attached to 1,3,4-thiadiazole ring); 132.4 (phenyl ring 
attached to 1,3,4 thiadiazole ring); 126.4 (C5, 4-
quinazolinone ring); 133.8 (C7, 4-quinazolinone ring); 135.3 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.5 (C12, styryl group attached to 4-
quinazolinone ring); 148.3 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.1 (C10, 4-quinazolinone ring;158.4 
(C2, 4-quinazolinone ring ; 160.6 (C4, 4-quinazolinone ring). 
FAB Mass (m/z): 551 (Quassi-molecular ion peak) 
SB-6: (E)-3-(5-(((4-nitrophenylamino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-chloro styryl) quinazolin-4(3H)-
one 
Molecular formula: C25H17ClN6O3S; Molecular weight: 
516.96; TLC (Rf value): 0.61;  IR (cm-1): 3074 (C-H str.); 718 
(C-H def (oop);1734 (C=O str.); 1580 (N=O str.); 1350 (N-O 
str.); 1596 (C=C str.); 1542 (C-Cl str.); 2944 (C-H str.); 3020 
(C-H str.); 1380 (C-H def); 1456 (C-C str.); 1634 (C=C str.); 
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1239 (C-N str.); 658 (C-S str.). 13C NMR (ppm): 113.2 (C11, 
styryl group attached to 4-quinazolinone ring); 126.4 (C8, 4-
quinazolinone ring): 128.4 (C14 & C18, phenyl substituted 
styryl group attached to 4-quinazolinone ring); 114.9 (C9, & 
C12, 4-quinazolinone ring & phenyl ring attached to 1,3,4 
thiadiazole ring); 133.5 (C16, phenyl substituted styryl 
group attached to 4-quinazolinone ring); 129.1 (C6, 4-
quinazolinone ring);136.3 (C15, phenyl substituted styryl 
group attached to 4-quinazolinone ring & phenyl ring 
attached to 1,3,4-thiadiazole ring); 129.6 (phenyl ring 
attached to 1,3,4 thiadiazole ring);  126.3 (C5, 4-
quinazolinone ring); 133.4 (C7, 4-quinazolinone ring);135.1 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.2 (C12, styryl group attached to 4-
quinazolinone ring); 155.4 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.2 (C10, 4-quinazolinone ring); 158.6 
(C2, 4-quinazolinone ring);160.3 (C4, 4-quinazolinone ring). 
FAB Mass (m/z): 517 (Quassi-molecular ion peak). 
SB-7: (E)-3-(5-(((4-fluorophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-chloro styryl)quinazolin-4 (3H)-
one 
Molecular formula: C25H17ClFN5OS; Molecular weight: 
489.95; TLC (Rf value): 0.61; IR (cm-1): 3125 (C-H str.); 808 
(C-H def (oop); 1700 (C=O str.); 1590 (C=C str.); 533 (C-Cl 
str.); 2933 (C-H str.); 3050 (C-H str.); 1450 (C-H def); 1570 
(C-C str.); 1630 (C=C str.); 1348 (C-N str.); 1560 (C=N str.); 
575 (C-S str.); 1210 (C-Br str.); 1320 (C-F str.); 13C NMR 
(ppm): 113.3 (C11, styryl group attached to 4-quinazolinone 
ring); 126.2 (C8, 4-quinazolinone ring); 128.5 (C14 & C18, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring); 118.9 (C9, 4-quinazolinone ring & phenyl ring 
attached to 1,3,4 thiadiazole ring); 127.8 (C16, phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
127.9 (C6, 4-quinazolinone ring); 155.2 (C15 and C17, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring & phenyl ring attached to 1,3,4-thiadiazole ring); 116.3 
(phenyl ring attached to 1,3,4 thiadiazole ring); 126.3 (C5, 4-
quinazolinone ring); 133.7 (C7, 4-quinazolinone ring); 135.2 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.5 (C12, styryl group attached to 4-
quinazolinone ring); 144.9 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.5 (C10, 4-quinazolinone ring); 158.2 
(C2, 4-quinazolinone ring); 160.1 (C4, 4-quinazolinone ring); 
FAB Mass (m/z): 489 (Quassi-molecular ion peak). 
SB-8: (E)-3-(5-(((4-methylphenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-chloro styryl) quinazolin-4(3H)-
one 
Molecular formula: C26H20ClN5OS; Molecular weight: 485.99; 
TLC (Rf value): 0.61; IR (cm-1): 3092 C-H str. Aromatic ring; 
758 C-H def (oop); 1708 C=O str; 1578 (C=C str.); 1096 (C-Cl 
str.); 2841 (C-H str.); 3008 (C-H str.); 1442 (C-H def); 1466 
(C-C str.); 1608 (C=C str.); 1278 (C-N str.); 1505 (C=N str.); 
620 (C-S str.); 720 (C-Cl str.); 13C NMR (ppm); 113.3 (C11, 
styryl group attached to 4-quinazolinone ring); 126.2 (C8, 4-
quinazolinone ring); 128.4 (C14 & C18, phenyl substituted 
styryl group attached to 4-quinazolinone ring); 113.7 (C9, & 
C13, 4-quinazolinone ring & phenyl ring attached to 1,3,4 
thiadiazole ring); 127.5 (C16, phenyl substituted styryl 
group attached to 4-quinazolinone ring); 127.7 (C6, 4-
quinazolinone ring); 129.6 (C15 and C17, phenyl substituted 
styryl group attached to 4-quinazolinone ring & phenyl ring 
attached to 1,3,4-thiadiazole ring); 129.8 (phenyl ring 
attached to 1,3,4 thiadiazole ring); 126.2 (C5, 4-
quinazolinone ring); 133.7 (C7, 4-quinazolinone ring); 135.2 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.5 (C12, styryl group attached to 4-
quinazolinone ring); 146.4 (phenyl ring attached to 1,3,4 
thiadiazole ring; 120.1 (C10, 4-quinazolinone ring); 158.3 
(C2, 4-quinazolinone ring; 160.2 (C4, 4-quinazolinone ring); 
21.3 (CH3, phenyl ring). FAB Mass (m/z): 486 (Quassi-
molecular ion peak). 
SB-9: (E)-3-(5-(((4-ethylphenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-chloro styryl)quinazolin-4(3H)-
one 
Molecular formula: C27H22ClN5OS; Molecular weight: 500.01; 
TLC (Rf value): 0.61; IR (KBr, cm-1): 3159 (C-H str.); 761  (C-
H def (oop)); 1701(C=O str.); 1562 (C=C str.); 2907 (C-H 
str.); 3010 (C-H str.); 1375 (C-H def); 1439 (C-C str.); 1693 
(C=C str.); 1316 (C-N str.); 761 (C-S str.); 650 (C-Cl str.); 13C 
NMR (ppm): 113.3 (C11, styryl group attached to 4-
quinazolinone ring); 126.2(C8, 4-quinazolinone ring); 128.4 
(C14 & C18, phenyl substituted styryl group attached to 4-
quinazolinone ring); 113.4 (C9 & C13, 4-quinazolinone ring 
& phenyl ring attached to 1,3,4 thiadiazole ring); 127.1 (C16, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring); 127.4 (C6, 4-quinazolinone ring); 136.7 (C15, C17, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring & phenyl ring attached to 1,3,4-thiadiazole ring); 128.5 
(phenyl ring attached to 1,3,4 thiadiazole ring); 126.2 (C5,      
4-quinazolinone ring); 133.5 (C7, 4-quinazolinone ring); 
135.5 (C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.7 (C12, styryl group attached to 4-
quinazolinone ring); 146.5 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.2 (C10,4-quinazolinone ring; 158.3 
(C2, 4-quinazolinone ring); 160.6 (C4, 4-quinazolinone ring); 
28.2 CH2 (phenyl ring attached to 1,3,4-thiadiazole ring); 
14.5 (CH3 phenyl ring attached to 1,3,4-thiadiazole ring). 
FAB Mass (m/z): 500 (Quassi-molecular ion peak). 
SB-10: (E)-3-(5-(((4-methoxyphenyl)amino)methyl)-
1,3,4-thiadiazol-2-yl)-2-(4-chlorostyryl)quinazolin-
4(3H)-one 
Molecular formula: C26H20ClN5O2S; Molecular weight: 
501.99; TLC (Rf value): 0.61; IR (KBr, cm-1): 3157 (C-H str.); 
819 (C-H def (oop); 1703 (C=O str.); 1080 (C-O-C str.); 1559 
(C=C str.); 2909 (C-H str.); 3050 (C-H str.); 1417 (C-H def); 
1450 (C-C str.); 1609 (C=C str.); 1252 (C-N str.); 1519 (C=N 
str.); 615 (C-S str.); 650 (C-Cl str.) 13C NMR (ppm): 113.1 
(C11, styryl group attached to 4-quinazolinone ring); 126.2 
(C8, 4-quinazolinone ring); 128.3 (C14 & C18, phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
113.3 (C9, 4-quinazolinone ring & phenyl ring attached to 
1,3,4 thiadiazole ring); 127.6 (C16, phenyl substituted styryl 
group attached to 4-quinazolinone ring); 127.3 (C6, 4-
quinazolinone ring); 151.7 (C15 and C17, phenyl substituted 
styryl group attached to 4-quinazolinone ring & phenyl ring 
attached to 1,3,4-thiadiazole ring; 115.1 (phenyl ring 
attached to 1,3,4 thiadiazole ring); 126.5 (C5, 4-
quinazolinone ring; 133.4 (C7, 4-quinazolinone ring); 135.7 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring);  138.8 (C12, styryl group attached to 4-
quinazolinone ring); 141.6 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.3 (C10, 4-quinazolinone ring);  158.6 
(C2, 4-quinazolinone ring); 160.8 (C4, 4-quinazolinone ring; 
55.8 (OCH3, phenyl ring attached to 1,3,4-thiadiazole ring). 
FAB Mass (m/z): 501 (Quassi-molecular ion peak).  
SB-11: (E)-3-(5-(((4-ethoxyphenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-chloro styryl) quinazolin-4(3H)-
one 
Molecular formula: C27H22ClN5O2S; Molecular weight: 
516.01; TLC (Rf value): 0.61; IR (KBr, cm-1): 3159 (C-H str); 
822 (C-H def (oop); 1692(C=O str.); 1210 (C-O-C str.); 
1562 (C=C str.); 2907 (C-H str.); 3031 (C-H str.); 1438 (C-H 
def); 1450 (C-C str.); 1650 (C=C str.); 1313 (C-N str.); 1520 
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(C=N str.); 670 (C-S str.); 720 (C-Cl str.); 13 CNMR (ppm): 
113.1 (C11 due to styryl group attached to 4-quinazolinone 
ring); 126.3 (C8 4-quinazolinone ring); 128.4 (C14 & C18 
due to phenyl substituted styryl group attached to 4-
quinazolinone ring); 112.9 (C9, 4-quinazolinone ring & 
phenyl ring attached to 1,3,4 thiadiazole ring; 127.3 (C16 
due to phenyl substituted styryl group attached to 4-
quinazolinone ring); 127.5 (C6 due to 4-quinazolinone ring); 
150.4 (C15 and C17 phenyl substituted styryl group attached 
to 4-quinazolinone ring & phenyl ring attached to 1,3,4-
thiadiazole ring); 115.2 (C  & C  due to phenyl ring attached 
to 1,3,4 thiadiazole ring);126.1 (C5 due to 4-quinazolinone 
ring ); 133.3 (C7 due to 4-quinazolinone ring); 135.3 (C13, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring); 138.6 (C12 due to styryl group attached to 4-
quinazolinone ring); 140.9 (C  due to phenyl ring attached to 
1,3,4 thiadiazole ring);  120.1 (C10 due to 4-quinazolinone 
ring); 158.2 (C2 due to 4-quinazolinone ring); 160.5 (C4 due 
to 4-quinazolinone ring); 58.4 (CH2 phenyl ring attached to 
1,3,4-thiadiazole ring); 14.8 (CH3 phenyl ring attached to 
1,3,4-thiadiazole ring). FAB Mass (m/z): 516 Quassi-
molecular ion peak.   
SB-12: (E)-3-(5-(((4-chlorophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-nitro styryl) quinazolin-4(3H)-one 
Molecular formula: C25H17ClN6O3S; Molecular weight:
 516.96; TLC (Rf value): 0.61; IR (KBr, cm-1): 3160 
(C-H str.); 760 (C-H def (oop); 1693(C=O str.); 1590(C=C 
str.); 2902 (C-H str.); 3020 C-H str.); 1373 (C-H def); 1437 
(C-C str.); 1580 (N=O str.); 1370 (N-O str.); 1610 (C=C str.); 
1316 (C-N str.) 1568 (C=N str.); 667 (C-S str.); 499 (C-Cl 
str.). 13C NMR (ppm): 113.1 (C11, styryl group 
attached to 4-quinazolinone ring); 126.3 (C8 due to 4-
quinazolinone ring); 129.0 (C14 & C18, phenyl substituted 
styryl group attached to 4-quinazolinone ring); 114.9 (C9, C  
& C  due to  4-quinazolinone ring & phenyl ring attached to 
1,3,4 thiadiazole ring); 147.1 (C16 due to phenyl substituted 
styryl group attached to 4-quinazolinone ring); 127.3 (C6 
due to 4-quinazolinone ring); 123.8 (C15 and C17, C   due to 
phenyl substituted styryl group attached to 4-quinazolinone 
ring &phenyl ring attached to 1,3,4-thiadiazole ring); 129.6 
(phenyl ring attached to 1,3,4 thiadiazole ring); 126.1 (C5 
due to 4-quinazolinone ring); 133.7 (C7 due to 4-
quinazolinone ring); 141.3 (C13 due to phenyl substituted 
styryl group attached to 4-quinazolinone ring); 138.2 (C12 
due to styryl group attached to 4-quinazolinone ring); 147.4 
(phenyl ring attached to 1,3,4 thiadiazole ring);120.8 (C10 
due to 4-quinazolinone ring); 158.2 (C2, 4-quinazolinone 
ring); 160.3 (C4, 4-quinazolinone ring).  FAB Mass (m/z): 
517 Quassi-molecular ion peak. 
SB-13: (E)-3-(5-(((4-bromophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-nitro styryl) quinazolin-4(3H)-one 
Molecular formula: C25H17BrN6O3S; Molecular weight: 
561.41; TLC (Rf value): 0.61; IR (KBr, cm-1): 3162.6 (C-H 
str.); 824.6 (C-H def (oop)); 1695.3 (C=O str.); 1570 (C=C 
str.); 2914 (C-H str.); 3080 (C-H str.); 1580 (N=0 str.); 1370 
(N-O str.); 1368 (C-H def); 1437 (C-C str.); 1610 (C=C str.); 
1254 (C-N str.); 1530 (C=N str.); 618 (C-S str.); 560 (C-Cl 
str.) 13C NMR (ppm): 113.3 (C11, styryl group attached to 4-
quinazolinone ring); 126.2 (C8, 4-quinazolinone ring); 129.2 
(C14 & C18, phenyl substituted styryl group attached to 4-
quinazolinone ring); 114.5(C9 & C13, 4-quinazolinone ring & 
phenyl ring attached to 1,3,4 thiadiazole ring); 147.3 (C16, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring); 127.1 (C6, 4-quinazolinone ring); 115.1 (C15 and C17, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring & phenyl ring attached to 1,3,4-thiadiazole ring); 132.4 
(phenyl ring attached to 1,3,4 thiadiazole ring); 126.3 (C5, 4-
quinazolinone ring); 133.5 (C7, 4-quinazolinone ring); 141.1 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.4 (C12, styryl group attached to 4-
quinazolinone ring); 148.3 (C  due to phenyl ring attached to 
1,3,4 thiadiazole ring; 120.3 (C10, 4-quinazolinone ring); 
158.4 (C2, 4-quinazolinone ring); 160.1 (C4, 4-quinazolinone 
ring). FAB Mass (m/z):  561 (Quassi-molecular ion peak). 
SB-14: (E)-3-(5-(((4-nitrophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-nitro styryl)quinazolin-4(3H)-one 
Molecular formula: C25H17N7O5S; Molecular weight: 527.51; 
TLC (Rf value): 0.61; IR (KBr, cm-1): 3148 (C-H str.); 824 (C-
H def (oop); 1708 (C=O str.); 1556 (C=C str.); 1560 (N=0 
str.); 1320 (N-O str.); 2893.2  (C-H str.);  3029(C-H str.); 
1436 (C-H def); 1420 (C-C str.); 1600 (C=C str.); 1311 (C-N 
str.); 1520 (C=N str.); 633 (C-S str.). 13C NMR (ppm): 113.1 
(C11, styryl group attached to 4-quinazolinone ring); 126.3 
(C8, 4-quinazolinone ring); 129.2 (C14 & C18, phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
114.4 (C9, 4-quinazolinone ring & phenyl ring attached to 
1,3,4 thiadiazole ring); 147.4 (C16, phenyl substituted styryl 
group attached to 4-quinazolinone ring); 127.3 ( C6, 4-
quinazolinone ring); 136.3 (C15 and C17, phenyl substituted 
styryl group attached to 4-quinazolinone ring & phenyl ring 
attached to 1,3,4-thiadiazole ring); 127.5 (phenyl ring 
attached to 1,3,4 thiadiazole ring); 126.3 (C5, 4-
quinazolinone ring); 133.7(C7, 4-quinazolinone ring); 141.1 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.3 (C12, styryl group attached to 4-
quinazolinone ring); 155.4 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.5 (C10, 4-quinazolinone ring); 158.4 
(C2, 4-quinazolinone ring); 160.2 (C4, 4-quinazolinone ring. 
FAB Mass (m/z): 527 (Quassi-molecular ion peak). 
SB-15: (E)-3-(5-(((4-fluorophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-nitro styryl) quinazolin-4(3H)-one 
Molecular formula: C25H17FN6O3S; Molecular weight: 500.50; 
TLC (Rf value): 0.61; IR (KBr, cm-1): 3161 (C-H str.); 820 (C-
H def (oop); 1692 (C=O str); 1564 (C=Cstr.);1580(N=0 str.); 
1370(N-O str.); 2903 (C-H str.) 3032 (C-H str.); 1376(C-H 
def); 1438(C-C str.); 1610 (C=C str.); 1315 (C-N str.); 1530 
(C=N str.); 608 (C-S str.); 1320  (C-F str.).13C NMR (ppm): 
113.3 (C11, styryl group attached to 4-quinazolinone ring 
126.5 (C8, 4-quinazolinone ring); 129.0 (C14 & C18, phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
118.9 (C9  & C13, 4-quinazolinone ring & phenyl ring 
attached to 1,3,4 thiadiazole ring); 147.1 (C16, phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
127.1 (C6, 4-quinazolinone ring); 123.4 (C15 and C17, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring & phenyl ring attached to 1,3,4-thiadiazole ring. 116.3 
(phenyl ring attached to 1,3,4 thiadiazole ring; 126.3 (C5, 4-
quinazolinone ring); 133.8 (C7, 4-quinazolinone ring; 141.1 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.6 (C12, styryl group attached to 4-
quinazolinone ring); 144.9 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.4 (C10, 4-quinazolinone ring); 158.3 
(C2, 4-quinazolinone ring); 160.1 (C4, 4-quinazolinone ring). 
FAB Mass (m/z): 500 (Quassi-molecular ion peak). 
SB-16: (E)-3-(5-(((4-chlorophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-methyl styryl) quinazolin-4(3H)-
one 
Molecular formula: C26H20ClN5OS; Molecular weight: 485.99; 
TLC (Rf value): 0.61; IR (KBr, cm-1): 3117.3 (C-H str.); 752.8 
C-H def (oop); 1689.5 (C=O str.); 1594 (C=C str.); 2917 (C-H 
str.); 3020 (C-H str.); 1448.3 (C-H def); 1610(C=C str.); 
1311(C-N str.); 1519(C=N str.); 645 (C-S str.); 464.4 (C-Cl 
str.). 13C NMR (ppm) 113.4 (C11, styryl group attached to 4-
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quinazolinone ring); 127.3 (C8, 4-quinazolinone ring); 128.5 
(C14 & C18, phenyl substituted styryl group attached to 4-
quinazolinone ring); 114.4 (C9, 4-quinazolinone ring & 
phenyl ring attached to 1,3,4 thiadiazole ring); 137.6 (C16, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring); 127.1 (C6, 4-quinazolinone ring); 128.9 (C15 and C17, 
phenyl substituted styryl group attached to 4-quinazolinone 
ring & phenyl ring attached to 1,3,4-thiadiazole ring); 129.4 
(phenyl ring attached to 1,3,4 thiadiazole ring); 126.5 (C5,  
4-quinazolinone ring); 133.4 (C7,  4-quinazolinone ring); 
132.2 (C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.4 (C12, styryl group attached to 4-
quinazolinone ring); 147.4 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.3 (C10, 4-quinazolinone ring); 158.1 
(C2, 4-quinazolinone ring); 160.7 (C4, 4-quinazolinone ring); 
21.3 (CH3; phenyl substituted styryl group attached to 4-
quinazolinone ring). FAB Mass (m/z):  486 Quassi-molecular 
ion peak. 
SB-17: (E)-3-(5-(((4-bromophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-methyl styryl) quinazolin-4(3H)-
one 
Molecular formula: C26H20BrN5OS; Molecular weight: 530.44; 
TLC (Rf value)0.61; IR (KBr, cm-1): 3163.3 (C-H str.); 822 (C-
H def (oop); 1691 (C=O str.); 1568.1 (C=C str.); 2911 (C-H 
str.); 3032 (C-H str.); 1374.6 (C-H def); 1438.2 (C-C str); 
1600 (C=C str.); 1313.7 (C-N str.); 1520 (C=N str.); 670 (C-S 
str.); 502.5 (C-Br str.). 13C NMR (ppm): 113.3 (C11, styryl 
group attached to 4-quinazolinone ring); 127.5 (C8, 4-
quinazolinone ring); 128.3 (C14 & C18, phenyl substituted 
styryl group attached to 4-quinazolinone ring); 114.5 (C9 & 
C13, 4-quinazolinone ring & phenyl ring attached to 1,3,4 
thiadiazole ring); 137.5 (C16, phenyl substituted styryl 
group attached to 4-quinazolinone ring); 127.6 (C6, 4-
quinazolinone ring); 118.7 (C15 and C17, phenyl substituted 
styryl group attached to 4-quinazolinone ring &enyl ring 
attached to 1,3,4-thiadiazole ring); 132.4 (phenyl ring 
attached to 1,3,4 thiadiazole ring); 126.2 (C5,  4-
quinazolinone ring); 133.1 (C7,  4-quinazolinone ring); 132.1 
(C13, phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.2 (C12, styryl group attached to 4-
quinazolinone ring); 148.5 (phenyl ring attached to 1,3,4 
thiadiazole ring); 120.1 (C10, 4-quinazolinone ring); 158.7 
(C2, 4-quinazolinone ring; 160.2 (C4, 4-quinazolinone ring); 
21.1 (CH3 phenyl substituted styryl group attached to 4-
quinazolinone ring). FAB Mass (m/z):530 Quassi-molecular 
ion peak (M+H)+ 
SB-18: (E)-3-(5-(((4-chlorophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-methoxy styryl) quinazolin-4(3H)-
one 
Molecular formula: C26H20ClN5O2S; Molecular weight: 
501.99; TLC (Rf value): 0.61; IR (KBr, cm-1): 3166.3 (C-H 
str.); 826.4(C-H def (oop); 1690.1 (C=O str.); 1579 (C=C str.); 
2918 (C-H str.); 3020 (C-H str.); 1369.7(C-H def); 1439.1 (C-
C str.); 1610 (C=C str.); 1325 (C-N str.); 1540(C=N str.); 666 
(C-S str.); 495.6 (C-Cl str.). 13C NMR (ppm): 113.3 (C11 due 
to styryl group attached to 4-quinazolinone ring); 127.1 C8 
due to 4-quinazolinone ring); 130 (C14 & C18 due to phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
114.9 (C9, 4-quinazolinone ring & phenyl ring attached to 
1,3,4 thiadiazole ring; 159 (C16 due to phenyl substituted 
styryl group attached to 4-qinazolinone ring); 127.4 (C6, 4-
quinazolinone ring); 114 (C15, C17 phenyl substituted styryl 
group attached to 4-quinazolinone ring &enyl ring attached 
to 1,3,4-thiadiazole ring); 129.6 (phenyl ring attached to 
1,3,4 thiadiazole ring); 126.2 (C5 due to 4-quinazolinone 
ring); 133.5 (C7 due to 4-quinazolinone ring); 127.5(C13 due 
to phenyl substituted styryl group attached to 4-
quinazolinone ring); 138.3 (C12 due to styryl group attached 
to 4-quinazolinone ring); 147.4 (phenyl ring attached to 
1,3,4 thiadiazole ring); 120.1(C10, 4-quinazolinone ring); 
158.3 (C2 due to 4-quinazolinone ring); 160.4 (C4 due to 4-
quinazolinone ring); 21.3 (OCH3); phenyl substituted styryl 
group attached to 4-quinazolinone ring. FAB Mass (m/z): 
502 (Quassi-molecular ion peak). 
SB-19: (E)-3-(5-(((4-bromophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-methoxy styryl) quinazolin-4(3H)-
one 
Molecular formula: C26H20BrN5O2S; Molecular weight: 
546.44; TLC (Rf value): 0.61; IR (KBr, cm-1): 3163 C-H str; 
824 (C-H def (oop); 1695 (C=O str.); 1565 (C=C str.); 2909 
(C-H str.); 3050 (C-H str.); 1368 (C-H def); 1440(C-C str.); 
1600(C=C str.); 1322 (C-N str.); 1520 (C=N str.); 619(C-S 
str.); 720 (C-Br str.). 13C NMR (ppm) 113.3 (C11 due to 
styryl group attached to 4-quinazolinone ring) 127.5 C8 
due to 4-quinazolinone ring); 130.3 (C14 & C18 due to 
phenyl substituted styryl group attached to 4-quinazolinone 
ring); 114.5 (C9, C  & C  due to  4-quinazolinone ring & 
phenyl ring attached to 1,3,4 thiadiazole ring); 159.6 (C16 
due to phenyl substituted styryl group attached to 4-
quinazolinone ring); 127.3 (C6 due to 4-quinazolinone ring); 
115.1 (C15 and C17, C   due to phenyl substituted styryl 
group attached to 4-quinazolinone ring &phenyl ring 
attached to 1,3,4-thiadiazole ring); 132.4 (phenyl ring 
attached to 1,3,4 thiadiazole ring); 126.6 (C5 due to 4-
quinazolinone ring); 133.1(C7 due to 4-quinazolinone ring); 
127.6 (C13 due to phenyl substituted styryl group attached 
to 4-quinazolinone ring); 138.7 (C12 due to styryl group 
attached to 4-quinazolinone ring); 148.3( phenyl ring 
attached to 1,3,4 thiadiazole ring); 120.3 (C10 due to 4-
quinazolinone ring); 158 (C2 due to 4-quinazolinone ring); 
160.7 (C4 due to 4-quinazolinone ring); 55.8OCH3; phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
FAB Mass (m/z): 546 (Quassi-molecular ion peak). 
SB-20: (E)-3-(5-(((4-fluorophenyl)amino)methyl)-1,3,4-
thiadiazol-2-yl)-2-(4-methoxy styryl) quinazolin-4(3H)-
one 
Molecular formula: C26H20FN5O2S; Molecular weight: 485.33; 
IR (KBr, cm-1): 3147 (C-H str.); 823 (C-H def) (oop); 1706 
(C=O str.); 1500 (C=C str.); 2807(C-H str.); 3020 (C-H str.); 
1377(C-H def); 1434 (C-C str.); 1600`(C=C str.); 
1311(C-N str.); 1558 (C=N str.); 681 (C-S str.); 710 (C-Br 
str.); 13C NMR (ppm): 113.3 (C11 due to styryl group 
attached to 4-quinazolinone ring); 127.3 (C8 due to 4-
quinazolinone ring); 130.1 (C14 & C18 due to phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
118.9(C9, C  & C  due to  4-quinazolinone ring & phenyl ring 
attached to 1,3,4 thiadiazole ring); 159.8 (C16 due to phenyl 
substituted styryl group attached to 4-quinazolinone ring); 
127.1 (C6 due to 4-quinazolinone ring); 114.2 (C15 and 
C17due to phenyl substituted styryl group attached to 4-
quinazolinone ring & phenyl ring attached to 1,3,4-
thiadiazole ring); 116.3 (phenyl ring thiadiazole ring); 126.2 
(C5 due to 4-quinazolinone ring); 133.5 (C7 due to 4-
quinazolinone ring); 127.3(C13 due to phenyl substituted 
styryl group attached to 4-quinazolinone ring); 138.3 (C12 
due to styryl group attached to 4-quinazolinone ring); 144.9 
(phenyl ring attached to 1,3,4 thiadiazole ring); 120.1 (C10 
due to 4-quinazolinone ring); 158.4 ( C2 due to 4-
quinazolinone ring); 160.2 (C4 due to 4-quinazolinone ring); 
55.5 (OCH3; phenyl substituted styryl group attached to 4-
quinazolinone ring). FAB Mass (m/z):  485 (Quassi-
molecular ion peak). 
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Table 1: List of synthesized compounds 
 
Code Chemical name Ar R1 R2 
SB-1 (E)-3-(5-(((4-chlorophenyl) amino) methyl)-1,3,4-thiadiazol-2-yl)-2-
styrylquinazolin-4(3H)-one 
-C6H5 -C6H5Cl H 
SB-2 (E)-3-(5-(((4-bromophenyl) amino) methyl)-1,3,4-thiadiazol-2-yl)-2-
styrylquinazolin-4(3H)-one 
-C6H5 -C6H5Br H 
SB-3 (E)-3-(5-(((4-nitrophenyl) amino) methyl)-1,3,4-thiadiazol-2-yl)-2-
styrylquinazolin-4(3H)-one 
-C6H5 -C6H5NO2 H 
SB-4 (E)-3-(5-(((4-chlorophenyl) amino) methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
chlorostyryl) quinazolin-4(3H)-one 
-C6H5Cl -C6H5Cl H 
SB-5 (E)-3-(5-(((4-bromophenyl) amino) methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
chlorostyryl) quinazolin-4(3H)-one 
-C6H5Cl -C6H5Br H 
SB-6 (E)-3-(5-(((4-nitrophenyl) amino) methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
chlorostyryl)quinazolin-4(3H)-one 
-C6H5Cl -C6H5NO2 H 
SB-7 (E)-3-(5-(((4-fluorophenyl) amino) methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
chlorostyryl) quinazolin-4(3H)-one 
-C6H5Cl -C6H5F H 
SB-8 (E)-3-(5-(((4-methylphenyl) amino) methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
chlorostyryl) quinazolin-4(3H)-one 
-C6H5Cl -C6H5CH3 H 
SB-9 (E)-3-(5-(((4-ethylphenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
chlorostyryl)quinazolin-4(3H)-one 
-C6H5Cl -C6H5C2H5 H 
SB-10 (E)-3-(5-(((4-methoxyphenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
chlorostyryl) quinazolin-4(3H)-one 
-C6H5Cl -C6H5OCH3 H 
SB-11 (E)-3-(5-(((4-ethoxyphenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
chlorostyryl) quinazolin-4(3H)-one 
-C6H5Cl -C6H5OC2H5 H 
SB-12 (E)-3-(5-(((4-chlorophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
nitrostyryl) quinazolin-4(3H)-one 
-C6H5NO2 -C6H5Cl H 
SB-13 (E)-3-(5-(((4-bromophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
nitrostyryl) quinazolin-4(3H)-one 
-C6H5NO2 -C6H5Br H 
SB-14 (E)-3-(5-(((4-nitrophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
nitrostyryl)quinazolin-4(3H)-one 
-C6H5NO2 -C6H5NO2 H 
SB-15 (E)-3-(5-(((4-fluorophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
nitrostyryl) quinazolin-4(3H)-one 
-C6H5NO2 -C6H5F H 
SB-16 (E)-3-(5-(((4-chlorophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
methylstyryl) quinazolin-4(3H)-one 
-C6H5CH3 -C6H5Cl H 
SB-17 (E)-3-(5-(((4-bromophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
methylstyryl) quinazolin-4(3H)-one 
-C6H5CH3 -C6H5Br H 
SB-18 (E)-3-(5-(((4-chlorophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
methoxystyryl) quinazolin-4(3H)-one 
-C6H5OCH3 -C6H5Cl H 
SB-19 (E)-3-(5-(((4-bromophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
methoxystyryl) quinazolin-4(3H)-one 
-C6H5OCH3 -C6H5Br H 
SB-20 (E)-3-(5-(((4-fluorophenyl)amino)methyl)-1,3,4-thiadiazol-2-yl)-2-(4-
methoxystyryl) quinazolin-4(3H)-one 
-C6H5OCH3 -C6H5F H 
 
Pharmacological evaluation: 
Animals: 
Albino mice of either sex (20-30 g) were used as 
experimental animals for anticonvulsant. Animals were kept 
in wire-mesh cages in a restricted-access room for one week 
before the experiments. Twelve days wash period was 
allowed prior to start of next study. The animals were fed 
with standard lab pellets and purified water. Prior to the ad 
libitum experiments animals were fasted for 12 h. All the 
test compounds were suspended in 0.5% w/v methyl 
cellulose. In each of the experiment a control group was 
made which received the vehicle (0.5% w/v methyl 
cellulose). All the experiments were carried out according to 
protocols approved by the Institutional Animal Ethical 
Committee, Baba Loknath Institute of Pharmacy Sciences 
and Research Centre, Sagar (Committee registration number 
CPCSEA/April/2018/01 and Letter reference number is 
Animal ethical committee BLIPS/IAEC/2018/01 dated 
19/04/2018).
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Table 2: Physico chemical properties of the synthesized compounds 
S. No. Code Percent Yield Melting point (°C) Mol. Formula Mol. Weight 
1.  SB-1 62 248-250 C25H18ClN5OS 471.96 
2.  SB-2 75 278-280 C25H18BrN5OS 516.41 
3.  SB-3 68 282-284 C25H18N6O3S 482.51 
4.  SB-4 69 246-248 C25H17Cl2N5OS 506.41 
5.  SB-5 64 262-264 C25H17BrClN5OS 550.86 
6.  SB-6 66 289-291 C25H17ClN6O3S 516.96 
7.  SB-7 68 >300* C25H17ClFN5OS 489.95 
8.  SB-8 78 244-245 C26H20ClN5OS 485.99 
9.  SB-9 64 212-214 C27H22ClN5OS 500.01 
10.  SB-10 63 243-245 C26H20ClN5O2S 501.99 
11.  SB-11 57 >300* C27H22ClN5O2S 516.01 
12.  SB-12 66 276-278 C25H17ClN6O3S 516.96 
13.  SB-13 76 215-217 C25H17BrN6O3S 561.41 
14.  SB-14 63 282-284 C25H17N7O5S 527.51 
15.  SB-15 68 >300* C25H17FN6O3S 500.50 
16.  SB-16 71 286-288 C26H20ClN5OS 485.99 
17.  SB-17 64 289-291 C26H20BrN5OS 530.44 
18.  SB-18 58 297-299 C26H20ClN5O2S 501.99 
19.  SB-19 45 244-245 C26H20BrN5O2S 546.44 
20.  SB-20 60 272-274 C26H20FN5O2S 485.33 
* Melting point at their decomposition. 
 
Pharmacological evaluation of Synthesized compounds 
Anticonvulsant evaluation of(E)-3-(5-(substituted 
aminomethyl)-1,3,4-thiadiazol-2-yl)-2-styryl quinazolin-
4(3H)-one was done by the anticonvulsant drug 
development (ADD) program protocol. The profile of 
anticonvulsant activity was established after injection by the 
i.p. MES pattern test20. Subcutaneous pentylentetrazol (sc-
PTZ)21 and subcutaneous pentylenetetrazole (scPTZ) seizure 
threshold test. Minimal motor impairment was measured by 
the roto-rod (neurotoxicity, NT) test using doses of 30, 100 
and 300 mg/kg at two different time intervals22. 
Study protocol 
Healthy young swiss albino mice weighing between 20-30 
gm were used. Before the administration of the test samples, 
standard and control, the mice were first tested by giving 
current of 50 mA for 0.2 seconds using electro 
convulsometer. Those animals which showed characteristic 
course of convulsions were selected for experiment. The 
selected animals were divided into three groups of six 
animals each. After 1 hour of administration of the standard 
drug (phenytoin) and the test samples the electric shock was 
induced. The different phases of convulsions i.e. tonic 
flexion, tonic extensor, clonic convulsion, stupor and 
recovery time or death were observed. The time (seconds) 
spent by the animals in each phase was recorded. The 
percentage protection provided by the standard and test 
samples was calculated. The scPTZ test was performed by 
administering PTZ dissolved in 0.9% NaCl solution in 
posterior midline of the animals. A minimal time of 30 min 
consequent to administration of PTZ was used for seizure 
detection. Protection was referred to as the failure to 
observe an episode of clonic convulsions of least 5s duration 
during this time period. 
Anticonvulsant screening 
Initially all the compounds were administered i.p. in a 
volume of 0.01 ml/gm body weight for mice at doses of 30, 
100, 300 mg/kg to one to six animals. Activity was 
established using the MES, scPTZ tests and these data are 
presented in table 3. 
Neurotoxicity screening 
Minimal motor impairment was measured in mice by the 
roto-rod test. The mice were trained to stay on an 
accelerating roto-rod thatrotates at six revolutions per 
minute. The rod diameter was 3.2cm. Neurotoxicity was 
indicated by the inability of the animal to maintain 
equilibrium on the rod for at least 1 min in each of the three 
trials. The data was presented in table 3. 
RESULTS AND DISCUSSION 
Spectral analysis 
The structures of the synthesized compounds (SB-1 to SB-
20) were characterized by IR, 13C NMR spectra, and mass 
spectroscopy. The infrared spectra of the synthesized 
compounds showed characteristic absorption band between 
1680-1700 cm-1 due to C=O str (quinazolinone ring); 
between 1600-1650 cm-1 due to C=C str. (vinyl group); 
between 1520-1560 cm-1 due to C=N str. (1,3,4-thiadiazole 
and quinazolinone ring), between 1210 to 1250 due to  C-N 
str of quinazolinone ring; between 550-780 cm-1 due to C-S 
str. (1,3,4-thiadiazole ring); 1090 cm-1 due to Ar-Cl str. and 
between 400-500 cm-1 due to aryl C-Cl in chloro containing 
compounds. In 13C-NMR spectra of the synthesized 
compounds C-2 and C-4 of quinazolinone were observed 
between 160-165 and 167—168 (δ, ppm) respectively, C-11 
and (C-5, C-6, C-7, C-8, C-9, C-10, C-12, C-13, C-14 & C18, C16, 
C15 & C17, C16) of quinazolinone were observed between 
112-115 and 122.1-147.8 (δ, ppm) respectively. Methoxy 
and methyl carbons were observed at 55.4 and 21 ppm. In 
addition peaks at δ 77.0 ppm for CDCl3 (solvent) and at δ 
39.0 ppm for DMSO-d6 (solvent) were also observed in 
respective cases. Elemental analysis of all synthesized 
compound were within the ±0.4% of the theoretical values. 
Generation of dense sooty flame and formation of oily layer 
after nitration of the compounds confirmed the presence of 
aromatic ring in all the synthesized compounds. In the FAB 
mass spectra two prominent peaks were observed. 
Anticonvulsant activity 
These synthesized compounds were screened for 
anticonvulsant activity. Anticonvulsant activity was 
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evaluated by maximal electroshock (MES), subcutaneous 
pentylene tetrazole (scPTZ) and neurotoxicity screens 
respectively.  Initial anticonvulsant activity and 
neurotoxicity data for the quinazolinone analogs are 
reported in table 3, along with the literature data on 
phenytoin, carbamazepine (Flaherty et al., 1996; Dimmock 
et al., 1996). Only Nine compounds as shown below showed 
protection against MES convulsion at dose levels as 
mentioned against their names. Compounds SB-1, SB-6, SB-
9, SB-12, SB-16 has shown the effect thirty minutes after 
administration of 30mg/kg of the drug (Table 3). In the 
ScPTZ model, only 8 compounds i.e. SB-3, SB-5, SB-8, SB-9, 
SB-10, SB-13, SB-17 and SB-18 showed protection of the 
convulsions but that too at the dose level of 300 mg/kg.  Out 
of these compounds showing protection two compounds i.e. 
SB-10 and SB-19 failed to protect the convulsion after 4 hrs 
of administration of the drugs.  Anticonvulsant effect (MES 
Test and scPTZ Test) of the synthesized compounds (SB-1 to 
SB-20) was depicted in Table 3. 
 
Table 3: Anticonvulsant effect of the synthesized compounds (SB-1 to SB-20) 
 
 
S. No. Code No. Ar R1 R2 Minimum Active Dose (mg/kg)a Neurotoxicity Dose 
(mg/kg)b MES Test scPTZ Test 
0.5h 4h 0.5h 4h 0.5h 4h 
1 SB-1 -C6H5 -C6H5Cl H 30 - - - - - 
2 SB-2 -C6H5 -C6H5Br H - - - - - - 
3 SB-3 -C6H5 -C6H5NO2 H - 100 - - - - 
4 SB-4 -C6H5Cl -C6H5Cl H 100 100 - - - - 
5 SB-5 -C6H5Cl -C6H5Br H - 100 -       - -       - 
6 SB-6 -C6H5Cl -C6H5NO2 H 30 100 - - - - 
7 SB-7 -C6H5Cl -C6H5F H - 300 100 - 100 - 
8 SB-8 -C6H5Cl -C6H5CH3 H - 100 - 100 - 100 
9 SB-9 -C6H5Cl -C6H5C2H5 H 30 - - - - - 
10 SB-10 -C6H5Cl -C6H5OCH3 H 100 300 - 300 - - 
11 SB-11 -C6H5Cl C6H5OC2H5 H - 300 - - - - 
12 SB-12 -C6H5NO2 -C6H5Cl H 30 100 - - - - 
13 SB-13 -C6H5NO2 -C6H5Br H - - 100 - 100 - 
14 SB-14 -C6H5NO2 -C6H5NO2 H - - - 300 - - 
15 SB-15 -C6H5NO2 -C6H5F H - 100 300 - 300 - 
16 SB-16 -C6H5CH3 -C6H5Cl H 30 300 - - - - 
17 SB-17 -C6H5CH3 -C6H5Br H - - - - - - 
18 SB-18 -C6H5OCH3 -C6H5Cl H - - - - - - 
19 SB-19 -C6H5OCH3 -C6H5Br H 100 - 100 - - - 
20 SB-20 -C6H5OCH3 -C6H5F H - - 300 - 300 - 
Phenytoin    30 30 - - 100 100 
Carbamazepine    30 100 100 300 100 300 
aDose in mg/kg at which bioactivity was observe in majority of the animals. The (-) sign indicates absence of protection of 
convulsion at the maximum dose administered i.e. 300 mg/kg. bDose in mg/kg at which neurotoxicity was observed in majority 
of the animal the (-) sign indicate absence neurotoxicity  at the maximum dose administered i.e. 300 mg/kg. 
 
In the earlier reports it was highlighted that the presence of 
electron richatom/group attached at the para position of the 
aryl ring showed increased potency in the MES screen. All 
the synthesized compounds were active in MES screen for a 
long duration of time (after 4 h). SB-6, SB-12, SB-14 and SB-
18 showed broad spectrum of anticonvulsant activity which 
is advantageous as compared to phenytoin. For broad 
spectrum the compounds should have electronegative 
substitution at least at either at R/Ar. Above mentioned 
compounds may be employed in both clonic-tonic (p) 
seizures and absence seizures (g). The most active 
compound of the series SB-1, SB-4, SB-6, SB-9, SB-12, SB-14, 
SB-14 and SB-18 (30 mg/kg i.p.; MES screen) contains un-
substituted R/Ar site which is very unique feature of the 
present study. Almost all, except SB-1, have chloro group 
substitution on either position i.e R/Ar. In most of the cases 
Cl, and nitro group phenyl ring in position of the 1,3,4-
thiadiazoles nucleus and Cl on phenyl ring of 4(3H)-
quinazolinone has shown the potent activity. Maximum 
compounds did not produce protection against either type of 
method, the reason may be quick metabolism of the 
compounds due to presence of carbonyl group or breakdown 
of chain at 2 position. In nutshell lipophilicity type of 
substitution, is sensitive towards metabolism, size of the 
molecule and concept of affinity and activity play major role 
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in determining the anticonvulsant property of the 
synthesized molecules. 
Neurotoxicity study 
Except 05 compounds, all other compounds showed no 
neurotoxicity at a maximum dose level of 300mg/kg. 
Compounds SB-7, SB-8, and SB-13 only showed the 
neurotoxicity at 100 mg/kg. Rest of the compounds SB-15 
and SB-20 i.e. showed neurotoxicity at 300 mg/kg dose level.  
About 89% compounds showed no neurotoxicity at a 
maximum dose level of 300mg/kg, which shows that they are 
non-toxic and safe used up to maximum dose levels. All the 
compounds were safe, nontoxic and no lethality was 
observed at the above mentioned dose levels. 
CONCLUSION 
This study concluded that these synthesized compounds 
have potential anticonvulsant activity and other 
pharmacological activity also prompted. Generally 
compounds possessing higher log p value showed higher 
decrease in locomotor activity. Bulkier compounds are more 
lipophilic and can cross blood brain barrier to exert their 
effect on CNS. Present study explored that substitution of 
4(3H)-quinazolinone at second and third H position of 
4(3H)-quinazolinone leads to the development of new 
chemical entities with potent sedative-hypnotic as compared 
to anticonvulsant activity. 
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